Table 1: Characteristics of patients receiving antianemic treatments in German routine practice.

Operable solid tumor ()Inoperable solid tumor ()Hematological malignancy ()Total
Day 1 treatmentTransfusionESAIV ironESA + IV ironTransfusionESAIV ironESA + IV ironTransfusionESAIV ironESA + IV iron

Number of patients []114513012362108102349537107962
Sex
 Male [%]36.827.540.050.050.043.552.958.857.951.480.057.148.0
Age at start of therapy
 Mean ± StD66.0 ± 12.864.2 ± 12.566.2 ± 9.566.4 ± 8.866.6 ± 10.664.4 ± 9.766.8 ± 10.669.1 ± 9.269.2 ± 11.564.8 ± 17.067.7 ± 14.367.4 ± 10.466.5 ± 11.3
CCI [0–36]
 Mean ± StD0.6 ± 1.60.5 ± 0.90.5 ± 0.90.8 ± 1.10.8 ± 1.30.6 ± 1.20.6 ± 1.10.6 ± 1.00.5 ± 0.90.8 ± 1.30.3 ± 0.71.4 ± 2.90.7 ± 1.2
Karnofsky Index [0–100]
 Mean ± StD81.6 ± 11.582.2 ± 9.287.7 ± 8.286.7 ± 4.978.7 ± 12.882.5 ± 8.878.8 ± 12.080.6 ± 10.782.6 ± 12.582.2 ± 10.077.0 ± 14.988.6 ± 6.980.7 ± 118
Most frequent solid cancers [%]
 Breast 16.741.216.78.314.125.011.814.714.7
 Colorectal 15.813.730.033.39.15.620.62.910.3
 Lung (NSCLC) 10.511.83.316.710.815.73.95.98.6
Tumor therapy [%]
 No therapy 6.13.32.50.92.06.35.420.03.1
 Chemotherapy 92.198.093.3100.088.195.486.394.176.881.140.085.788.4
 Other1.82.03.490.696.388.35.916.913.540.014.391.5
Baseline Hb
 Median [g/dL]8.79.39.69.68.69.59.69.48.59.29.610.88.9

Charlson Comorbidity Index.